News

Novo Nordisk shares are rising after the company cut its outlook. It’s been that kind of year.
Novo Nordisk on Wednesday managed the unusual feat of seeing its stock price rise after reducing its earnings outlook. But ...
Applied Clinical Trials Online6h
Novo Nordisk’s Sogroya Demonstrates Favorable Outcomes in Phase III Trial for Children’s Growth Disorders
The REAL8 basket study showed Sogroya (somapacitan) was non-inferior to Norditropin (somatropin) in improving yearly growth ...
Novo Nordisk's Sogroya Supports Effective Weekly Alternative To Daily Hormone Therapy Across Three Growth Disorders
Novo Nordisk A/S (NYSE:NVO) on Monday presented data from the phase 3 REAL8 basket study investigating once-weekly Sogroya ...
Why Novo Nordisk Stock Popped After Earnings
Novo Nordisk reports its results in Danish kroner (DKK) rather than U.S. dollars. Sales grew 19% year over year to 78.1 ...
Novo Nordisk Reports Positive Results for Growth Disorder Treatment
Novo Nordisk reported positive data from a late-stage trial of its once-weekly Sogroya treatment for children with growth disorders.
Currency hedging and new U.S. factories: Novo Nordisk CFO thinks Wegovy maker can outmaneuver global trade wars
Novo Nordisk is hedging and building its way around a global tariff war that may threaten the Wegovy maker’s plans to expand ...
Explore more
Novo Nordisk's CFO sceptical Trump executive order on drug manufacturing can cut timelines
Obesity drugmaker Novo Nordisk's CFO said on Wednesday he was sceptical that U.S. President Donald Trump's executive order to ...
Novo Nordisk: It's Not Been This Cheap For Many Years
Novo Nordisk's stock has plummeted over 60%, while also arguably losing market share to Eli Lilly. Click here to find out why ...
Novo Nordisk A/S (NVO): A Bull Case Theory
We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Kontra Investments. In this article, we will summarize the bulls’ thesis on NVO.
Novo Nordisk hopes to see US Wegovy sales recover soon
Drugmaker Novo Nordisk expects Wegovy weight-loss drug sales in the United States to start to recover once a ban on compound ...
Novo Nordisk Q1 2025: One Of The Best Deals You Can Get Right Now
Novo Nordisk's Q1 2025 results show a 19% sales increase, 20% operating income growth, and 14% net profit rise. Read why NVO ...